Name Targets Phase Tofacitinib JAK3>JAK1>JAK2 Filed INCB28050 JAK1=JAK2 Phase III GLPG0634 JAK1 Phase II VX-509 JAK3 Phase II

Table 4: Compare of several JAKs inhibitors’ treatment of rheumatoid arthritis.